CRISPR Therapeutics (NASDAQ:CRSP) Stock Rating Reaffirmed by Needham & Company LLC
Needham & Company LLC reaffirmed their buy rating on shares of CRISPR Therapeutics (NASDAQ:CRSP – Free Report) in a report published on Monday morning, Benzinga reports. The firm currently has a $88.00 price objective on the stock. CRSP has been the subject of several other research reports. Oppenheimer decreased their target price on CRISPR Therapeutics […]
More Stories
Trump Offers White House Press Secretary Job to UFC Chief Dana White
By Sylvia Xu President Donald Trump said on Saturday that he offered the White House press secretary job to Ultimate...
Cost of Living, AI Bubble Top Consumer Concerns in November: UMich
By Andrew Moran U.S. consumer sentiment rebounded this month, but concerns surrounding ongoing cost-of-living issues and a potential artificial intelligence...
Wendy’s Rejects $1.4 Billion Buyout Offer From Nelson Peltz-Led Group
By Bill Pan Wendy’s has rejected a $1.4 billion takeover offer from billionaire investor Nelson Peltz, saying the proposal “substantially...
Best Family Halloween Movies to Watch
Halloween movies for families is one of the most searched phrases before Halloween night every year. October is the perfect...
GOP Rep. Luna Wins Reelection to House District in Florida
By Zachary Stieber Rep. Anna Paulina Luna (R-Fla.) has won another term representing Florida in the U.S. House of Representatives....
National Veterans Parade Expected to Draw 50,000 to DC
By Timothy Frudd The National Veterans Parade is expected to draw 50,000 people to the streets of Washington on Sunday...